Mylan May Have Overcharged Medicaid $1.27 Billion for EpiPen

by Admin | June 12, 2017 4:17 pm

June 12, 2017—Medicaid may have overpaid drug manufacturer Mylan as much as $1.27 billion for the emergency allergy drug EpiPen from 2006 through 2016 because it was misclassified as a generic rather than brand-name drug, the Department of Health and Human Services Office of Inspector General told Senate Judiciary Chairman Chuck Grassley (R-Iowa) in a letter[1].  

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[2].    Already registered? Click here to login[3]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

Endnotes:
  1. letter: https://www.grassley.senate.gov/sites/default/files/constituents/HHS%20OIG%202nd%20EpiPen%20calculation%20letter%20for%20Senate%20Judiciary%20May%2031%202017_Redacted.pdf
  2. Click here to register: https://secure.340bhealth.org/340Binformed/Subscribe.aspx
  3. Click here to login: http://340binformed.org/reader-login/

Source URL: https://340binformed.org/2017/06/mylan-may-have-overcharged-medicaid-1-27-billion-for-epipen/

Copyright ©2024 340binformed.org unless otherwise noted.